Kips Bay Medical (KIPS) 0.51 $KIPS
Kips Bay Medical Provides Business Update and Reports First Quarter 2014 Results
GlobeNewswire - Thu May 08, 8:31AM CDT
Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting surgery, today provided a business update and announced financial results for its first quarter ended March 29, 2014.
Manny Villafana to Receive Honorary Doctoral Degree From the University of Iowa
GlobeNewswire - Mon May 05, 9:00AM CDT
Manny Villafana, Founder, Chairman & CEO of Kips Bay Medical, Inc. will receive an honorary Doctor of Science degree from the University of Iowa on Saturday May 17, 2014.
Kips Bay Medical to Host Business Update Conference Call on May 13, 2014
GlobeNewswire - Fri May 02, 8:30AM CDT
Manny Villafana, Chairman and CEO of Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS(R) Mesh, for use in coronary artery bypass grafting surgery, announced today that Kips Bay will release operating and financial results for the first quarter ended March 29, 2014 prior to the open of the regular trading market on Thursday, May 8, 2014. Villafana also announced that Kips Bay will hold a conference call to discuss its recent business developments at 9:00 A.M. Eastern Time / 8:00 A.M. Central Time on Tuesday, May 13, 2014.
Kips Bay Medical Announces the First eSVS(R) Mesh Implant in Warsaw Poland
GlobeNewswire - Mon Apr 21, 10:01AM CDT
Manny Villafana, Chairman and CEO of Kips Bay Medical Inc. (Nasdaq:KIPS), announced that on April 12, 2014, the first commercial implant of an eSVS Mesh was performed at the Military Institute of Medicine in Warsaw, Poland. This implant was performed under the direction of Cardiac Surgery Department Head Dr. Piotr Hendzel MD, Ph.D., and the presiding surgeon in the case was Dr. Grzegorz Suwalski MD PhD. Dr. Suwalski commented "I was very pleased with how easily the eSVS Mesh was applied to the vein graft and I believe that the eSVS Mesh technology represents a new tool for cardiac surgeons that has the potential to significantly improve the long-term outcomes for cardiac bypass surgery patients."
Kips Bay Medical wins US FDA's approval to expand eMESH I clincal feasibility study in the US
M2 - Tue Mar 18, 7:39AM CDT
Medical device company Kips Bay Medical (NasdaqCM:KIPS) revealed on Monday the receipt of approval from the US Food & Drug Administration (FDA) to include more US patients and US study sites under its 'eMESH I' clinical feasibility trial of its eSVS Mesh.
Kips Bay Medical Announces FDA Approval for U.S. Expansion of Its eMESH I Clincal Feasibility Study
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Kips Bay Medical, Inc. (Nasdaq:KIPS) along with Manny Villafana, its Founder, Chairman and CEO, announced today that the United States Food & Drug Administration ("FDA"
has granted an approval for Kips Bay Medical to include more U.S. patients and U.S. study sites in its "eMESH I" clinical feasibility trial of its eSVS Mesh.
Kips Bay Medical Provides Business Update and Reports Fourth Quarter and Full Year 2013 Results
GlobeNewswire - Wed Mar 12, 3:48PM CDT
Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting surgery, today provided a business update and announced financial results for its fourth quarter and full year ended December 31, 2013.
3 Stocks Under $10 Making Big Moves
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Kips Bay Medical Announces the First Austrian Implant of the eSVS Mesh
GlobeNewswire - Mon Feb 10, 8:00AM CST
Manny Villafana, Chairman and CEO of Kips Bay Medical Inc. (Nasdaq:KIPS), announced that on January 14, 2014, the first commercial implant of the Company's eSVS Mesh in Austria was performed at the Medical University of Vienna in Vienna, Austria. This implant was performed under the direction of Professor Dr. Gunther Laufer. The presiding surgeon in the case, Professor Dr. Sigrid Sandner, commented that the eSVS Mesh was easily deployed with no complications.
Elizabeth Arden, Inc. Announces Second Quarter Fiscal 2014 Results
Business Wire - Wed Feb 05, 5:59AM CST
Elizabeth Arden, Inc. (NASDAQ:RDEN), a global prestige beauty products company, announced today financial results for its second fiscal quarter ended December 31, 2013.
Kips Bay Medical Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Wed Jan 29, 10:45AM CST
Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, the eSVS Mesh, for use in coronary artery bypass grafting surgery, today announced the closing of its previously announced underwritten public offering of 5,250,000 shares of common stock and the sale of an additional 785,000 shares of common stock pursuant to the exercise in full by the underwriters of the over-allotment option granted to the underwriters in connection with the offering. The gross proceeds to Kips Bay from the offering, including the exercise of the over-allotment option by the underwriters, are $4,224,500, before deducting underwriting discounts and commissions and other offering expenses payable by Kips Bay.
Nasdaq stocks posting largest volume increases
AP - Fri Jan 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Kips Bay Medical Announces Pricing of Public Offering of 5,250,000 Shares of Common Stock
GlobeNewswire - Thu Jan 23, 7:47PM CST
Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, the eSVS(R) Mesh, for use in coronary artery bypass grafting surgery, today announced the pricing of its previously announced underwritten public offering. Kips Bay is offering 5,250,000 shares of common stock at a public offering price of $0.70 per share for gross proceeds of $3,675,000, prior to deducting the underwriting discount and estimated offering expenses. Kips Bay intends to use the net proceeds of this offering for working capital and general corporate purposes, including funding the process of seeking regulatory approval to market its eSVS Mesh in the United States and abroad, including continuing its human clinical trials.
Kips Bay Medical Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Jan 23, 3:16PM CST
Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, the eSVS(R) Mesh, for use in coronary artery bypass grafting surgery, today announced its intention, subject to market and other conditions, to commence a public offering of its common stock. Kips Bay intends to use the net proceeds of this offering for working capital and general corporate purposes, including funding the process of seeking regulatory approval to market its eSVS Mesh in the United States and abroad, including continuing its human clinical trials.
Kips Bay Medical to Present at the 25th Annual Piper Jaffray Health Care Conference in New York on December 3, 2013
Business Wire - Mon Nov 25, 8:00AM CST
Kips Bay Medical (NASDAQ:KIPS) announced that Manny Villafana, Chairman and Chief Executive Officer is scheduled to present at the 25th Annual Piper Jaffray & Co. Healthcare Conference at on Tuesday December 3, 2013 at 3:30 p.m. Eastern Time, at The New York Palace Hotel located at 455 Madison Avenue, New York, NY.
Kips Bay Medical Announces the First eSVS(R) Mesh Implant by the Emory University Cardiothoracic Clinical Research Unit
Business Wire - Wed Sep 18, 7:30AM CDT
Manny Villafana, Chairman and CEO of Kips Bay Medical Inc. (NASDAQ:KIPS), announced that on September 4, 2013, the Emory Heart & Vascular Center in Atlanta, Georgia, performed its first implant of an eSVS(R) Mesh. This implant was performed as part of the Kips Bay Medical eMESH I clinical feasibility trial currently being conducted for the U.S. Food and Drug Administration (FDA) in a number of preeminent cardiac surgery centers in both Europe and the United States.
Kips Bay Medical Chairman and CEO Manny Villafana to Present Keynote Address at the Aegis 2013 Health Care Conference
Business Wire - Thu Sep 12, 7:30AM CDT
Kips Bay Medical, Inc. (NASDAQ: KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS(R) Mesh, for use in coronary artery bypass grafting surgery (CABG), announced that Manny Villafana, its Chairman and Chief Executive Officer, has been invited to deliver a keynote address at the Aegis Capital Corp. 2013 Healthcare Conference on Thursday, September 26, 2013 at 8:00 p.m., Pacific Time, at The Encore at Wynn Las Vegas. Mr. Villafana is also scheduled to deliver a company presentation at the Conference earlier in the day at 8:30 a.m., Pacific Time.
Kips Bay Medical Provides Business Update
Business Wire - Wed Sep 04, 7:30AM CDT
Manny Villafana, Chairman and Chief Executive Officer of Kips Bay Medical, Inc. (NASDAQ:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS(R) Mesh, for use in coronary artery bypass grafting surgery (CABG), provided the following business update to Kips Bay shareholders and the financial community.
Kips Bay Medical Provides Business Update and Reports First Quarter 2014 Results
GlobeNewswire - Thu May 08, 8:31AM CDT
Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting surgery, today provided a business update and announced financial results for its first quarter ended March 29, 2014.
Manny Villafana to Receive Honorary Doctoral Degree From the University of Iowa
GlobeNewswire - Mon May 05, 9:00AM CDT
Manny Villafana, Founder, Chairman & CEO of Kips Bay Medical, Inc. will receive an honorary Doctor of Science degree from the University of Iowa on Saturday May 17, 2014.
Kips Bay Medical to Host Business Update Conference Call on May 13, 2014
GlobeNewswire - Fri May 02, 8:30AM CDT
Manny Villafana, Chairman and CEO of Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS(R) Mesh, for use in coronary artery bypass grafting surgery, announced today that Kips Bay will release operating and financial results for the first quarter ended March 29, 2014 prior to the open of the regular trading market on Thursday, May 8, 2014. Villafana also announced that Kips Bay will hold a conference call to discuss its recent business developments at 9:00 A.M. Eastern Time / 8:00 A.M. Central Time on Tuesday, May 13, 2014.
Kips Bay Medical Announces the First eSVS(R) Mesh Implant in Warsaw Poland
GlobeNewswire - Mon Apr 21, 10:01AM CDT
Manny Villafana, Chairman and CEO of Kips Bay Medical Inc. (Nasdaq:KIPS), announced that on April 12, 2014, the first commercial implant of an eSVS Mesh was performed at the Military Institute of Medicine in Warsaw, Poland. This implant was performed under the direction of Cardiac Surgery Department Head Dr. Piotr Hendzel MD, Ph.D., and the presiding surgeon in the case was Dr. Grzegorz Suwalski MD PhD. Dr. Suwalski commented "I was very pleased with how easily the eSVS Mesh was applied to the vein graft and I believe that the eSVS Mesh technology represents a new tool for cardiac surgeons that has the potential to significantly improve the long-term outcomes for cardiac bypass surgery patients."
Kips Bay Medical wins US FDA's approval to expand eMESH I clincal feasibility study in the US
M2 - Tue Mar 18, 7:39AM CDT
Medical device company Kips Bay Medical (NasdaqCM:KIPS) revealed on Monday the receipt of approval from the US Food & Drug Administration (FDA) to include more US patients and US study sites under its 'eMESH I' clinical feasibility trial of its eSVS Mesh.
Kips Bay Medical Announces FDA Approval for U.S. Expansion of Its eMESH I Clincal Feasibility Study
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Kips Bay Medical, Inc. (Nasdaq:KIPS) along with Manny Villafana, its Founder, Chairman and CEO, announced today that the United States Food & Drug Administration ("FDA"
has granted an approval for Kips Bay Medical to include more U.S. patients and U.S. study sites in its "eMESH I" clinical feasibility trial of its eSVS Mesh. Kips Bay Medical Provides Business Update and Reports Fourth Quarter and Full Year 2013 Results
GlobeNewswire - Wed Mar 12, 3:48PM CDT
Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting surgery, today provided a business update and announced financial results for its fourth quarter and full year ended December 31, 2013.
3 Stocks Under $10 Making Big Moves
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Kips Bay Medical Announces the First Austrian Implant of the eSVS Mesh
GlobeNewswire - Mon Feb 10, 8:00AM CST
Manny Villafana, Chairman and CEO of Kips Bay Medical Inc. (Nasdaq:KIPS), announced that on January 14, 2014, the first commercial implant of the Company's eSVS Mesh in Austria was performed at the Medical University of Vienna in Vienna, Austria. This implant was performed under the direction of Professor Dr. Gunther Laufer. The presiding surgeon in the case, Professor Dr. Sigrid Sandner, commented that the eSVS Mesh was easily deployed with no complications.
Elizabeth Arden, Inc. Announces Second Quarter Fiscal 2014 Results
Business Wire - Wed Feb 05, 5:59AM CST
Elizabeth Arden, Inc. (NASDAQ:RDEN), a global prestige beauty products company, announced today financial results for its second fiscal quarter ended December 31, 2013.
Kips Bay Medical Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Wed Jan 29, 10:45AM CST
Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, the eSVS Mesh, for use in coronary artery bypass grafting surgery, today announced the closing of its previously announced underwritten public offering of 5,250,000 shares of common stock and the sale of an additional 785,000 shares of common stock pursuant to the exercise in full by the underwriters of the over-allotment option granted to the underwriters in connection with the offering. The gross proceeds to Kips Bay from the offering, including the exercise of the over-allotment option by the underwriters, are $4,224,500, before deducting underwriting discounts and commissions and other offering expenses payable by Kips Bay.
Nasdaq stocks posting largest volume increases
AP - Fri Jan 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Kips Bay Medical Announces Pricing of Public Offering of 5,250,000 Shares of Common Stock
GlobeNewswire - Thu Jan 23, 7:47PM CST
Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, the eSVS(R) Mesh, for use in coronary artery bypass grafting surgery, today announced the pricing of its previously announced underwritten public offering. Kips Bay is offering 5,250,000 shares of common stock at a public offering price of $0.70 per share for gross proceeds of $3,675,000, prior to deducting the underwriting discount and estimated offering expenses. Kips Bay intends to use the net proceeds of this offering for working capital and general corporate purposes, including funding the process of seeking regulatory approval to market its eSVS Mesh in the United States and abroad, including continuing its human clinical trials.
Kips Bay Medical Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Jan 23, 3:16PM CST
Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, the eSVS(R) Mesh, for use in coronary artery bypass grafting surgery, today announced its intention, subject to market and other conditions, to commence a public offering of its common stock. Kips Bay intends to use the net proceeds of this offering for working capital and general corporate purposes, including funding the process of seeking regulatory approval to market its eSVS Mesh in the United States and abroad, including continuing its human clinical trials.
Kips Bay Medical to Present at the 25th Annual Piper Jaffray Health Care Conference in New York on December 3, 2013
Business Wire - Mon Nov 25, 8:00AM CST
Kips Bay Medical (NASDAQ:KIPS) announced that Manny Villafana, Chairman and Chief Executive Officer is scheduled to present at the 25th Annual Piper Jaffray & Co. Healthcare Conference at on Tuesday December 3, 2013 at 3:30 p.m. Eastern Time, at The New York Palace Hotel located at 455 Madison Avenue, New York, NY.
Kips Bay Medical Announces the First eSVS(R) Mesh Implant by the Emory University Cardiothoracic Clinical Research Unit
Business Wire - Wed Sep 18, 7:30AM CDT
Manny Villafana, Chairman and CEO of Kips Bay Medical Inc. (NASDAQ:KIPS), announced that on September 4, 2013, the Emory Heart & Vascular Center in Atlanta, Georgia, performed its first implant of an eSVS(R) Mesh. This implant was performed as part of the Kips Bay Medical eMESH I clinical feasibility trial currently being conducted for the U.S. Food and Drug Administration (FDA) in a number of preeminent cardiac surgery centers in both Europe and the United States.
Kips Bay Medical Chairman and CEO Manny Villafana to Present Keynote Address at the Aegis 2013 Health Care Conference
Business Wire - Thu Sep 12, 7:30AM CDT
Kips Bay Medical, Inc. (NASDAQ: KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS(R) Mesh, for use in coronary artery bypass grafting surgery (CABG), announced that Manny Villafana, its Chairman and Chief Executive Officer, has been invited to deliver a keynote address at the Aegis Capital Corp. 2013 Healthcare Conference on Thursday, September 26, 2013 at 8:00 p.m., Pacific Time, at The Encore at Wynn Las Vegas. Mr. Villafana is also scheduled to deliver a company presentation at the Conference earlier in the day at 8:30 a.m., Pacific Time.
Kips Bay Medical Provides Business Update
Business Wire - Wed Sep 04, 7:30AM CDT
Manny Villafana, Chairman and Chief Executive Officer of Kips Bay Medical, Inc. (NASDAQ:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS(R) Mesh, for use in coronary artery bypass grafting surgery (CABG), provided the following business update to Kips Bay shareholders and the financial community.
